Zhengye Biotechnology Holding (ZYBT) Receivables - Net (2023 - 2025)

Zhengye Biotechnology Holding (ZYBT) has 3 years of Receivables - Net data on file, last reported at $2.6 million in Q4 2025.

• Receivables - Net for Q4 2025 came in at $2.6 million, down 68.57% year-over-year; the trailing twelve-month figure through Dec 2025 was $2.6 million (down 68.57% YoY), and the FY2025 annual result was $5.2 million, down 50.13% from the prior year.
• Receivables - Net eased to $2.6 million in Q4 2025 per ZYBT's latest filing, from $5.2 million in the prior quarter.
• Over five years, Receivables - Net peaked at $10.3 million in Q4 2023 and troughed at $2.6 million in Q4 2025.
• A 3-year average of $6.6 million and a median of $6.7 million in 2024 frame the typical range for Receivables - Net.
• The sharpest annual moves came in 2024 and 2025: Receivables - Net declined 19.5% in 2024, then slumped 68.57% in 2025.
• A 3-year view of Receivables - Net shows it stood at $10.3 million in 2023, then retreated by 19.5% to $8.3 million in 2024, then tumbled by 68.57% to $2.6 million in 2025.
• Business Quant data shows ZYBT's Receivables - Net at $2.6 million in Q4 2025, $5.2 million in Q2 2025, and $8.3 million in Q4 2024.